ALI HEALTH's stock plummeted 5.19% during intraday trading on FRIDAY, reflecting significant downward pressure on the medical e-commerce sector.
The decline was driven by broad-based weakness across the medical e-commerce sector, with peers including JD Health, Ping An Good Doctor, and Meituan all experiencing substantial losses. This sector-wide selling pressure weighed heavily on ALI HEALTH's valuation.
Adding to the negative sentiment, UBS maintained its sell rating on ALI HEALTH and lowered its target price to HK$3.1, with the current share price approaching that bearish target. Furthermore, persistent institutional outflows have been observed, with southbound funds cumulatively net selling over 128 million shares over the past 20 trading days, exacerbating the downside pressure on the stock.
Comments